Ceeto Capital Group LLC grew its position in Humana Inc. (NYSE:HUM - Free Report) by 37.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,250 shares of the insurance provider's stock after acquiring an additional 890 shares during the quarter. Ceeto Capital Group LLC's holdings in Humana were worth $827,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in the company. Transcend Capital Advisors LLC lifted its holdings in Humana by 399.7% during the 4th quarter. Transcend Capital Advisors LLC now owns 3,643 shares of the insurance provider's stock valued at $924,000 after buying an additional 2,914 shares in the last quarter. FNY Investment Advisers LLC boosted its holdings in shares of Humana by 6,647.5% in the fourth quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider's stock valued at $6,916,000 after purchasing an additional 26,856 shares during the period. Retirement Systems of Alabama grew its stake in Humana by 735.9% in the fourth quarter. Retirement Systems of Alabama now owns 219,002 shares of the insurance provider's stock worth $55,563,000 after purchasing an additional 192,801 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Humana by 7.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 964,926 shares of the insurance provider's stock worth $244,811,000 after purchasing an additional 65,735 shares during the period. Finally, Secure Asset Management LLC bought a new stake in Humana during the 4th quarter valued at $244,000. 92.38% of the stock is owned by hedge funds and other institutional investors.
Humana Stock Performance
Shares of Humana stock traded down $1.30 on Wednesday, reaching $285.48. 1,338,411 shares of the stock were exchanged, compared to its average volume of 1,749,400. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The business has a 50 day moving average price of $265.57 and a two-hundred day moving average price of $270.22. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $34.46 billion, a price-to-earnings ratio of 28.69, a PEG ratio of 2.05 and a beta of 0.62.
Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.
Humana Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.24%. Humana's payout ratio is 35.58%.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on HUM. Truist Financial increased their price target on Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a research report on Friday, April 11th. JPMorgan Chase & Co. cut their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 18th. Robert W. Baird upped their price target on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research report on Tuesday. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a report on Wednesday, January 15th. Finally, StockNews.com upgraded Humana from a "hold" rating to a "buy" rating in a report on Monday, April 7th. Seventeen research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, Humana presently has an average rating of "Hold" and an average target price of $284.90.
View Our Latest Report on HUM
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
